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Abstract: 
Breast cancer is the most frequently occurring malignant neoplasm among women. Statistically, 
it constitutes 22,8% of all malignant neoplasms among females. Despite the fact that the causes 
of the disease remain unknown, a few risk factors are contributing to its development. 
Age, family history, type of lifestyle, hormones and genetic background have a significant 
association with occurrence of breast cancer. Due to the fact that time in which female sex 
hormones affect mammary gland is one of the most important risk factors of breast cancer 
development, more researchers focused on the use of drugs such as selective estrogen receptor 
modulators (SERMs) in the disease prevention. Tamoxifen has antiestrogenic effect. That 
results in the inhibition of both- growth factors release and synthesis by the tumour.  Moreover, 
this drug works as agonist, replacing oestrogen to many tissues, such as the ones in liver, bone, 
breast and uterus. In the literature there are many reports about the effectiveness of tamoxifen 
in the prevention of breast cancer. The drug, in addition to using it as adjuvant therapy for breast 
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cancer, can be used as a prophylactic of the disease. Side effects of the drug are rare, but they 
cannot be completely excluded. 
Breast cancer, which is currently the most common tumour in the globe, is a serious worldwide 
public health quandary. Tamoxifen is considered to be a pioneering drug as it is used in 
combined breast cancer therapy and also in chemoprophylaxis ,but every case of using the 
medicine should be considered individually to assess benefit-risk ratio. 
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Introduction 
Breast cancer is the most frequently occurring malignant neoplasm among women. Statistically, 
it constitutes 22,8% of all malignant neoplasms among females. It is the second most common 
cause of the death of women due to the cancer. It is also the most frequently occurring type of 
neoplasm in developed countries (USA, Western Europe), whereas in South Asia and Africa its 
incidence is much lower.[1] The 5-year survival rate of patients diagnosed in Poland in 2008-
2010 is 79%. The National Cancer Registry states that at the time of diagnosis in 2016, 66% of 
cases were local, 26% regional and about 7% generalized. Referring to data from 2010 (local 
advancement - 58% of cases, regional 26%, generalized 8%), an increase in the frequency of 
breast cancer detection at a less advanced stage was observed, however, still a large proportion 
of patients report to the doctor only when the disease is at serious stage of advancement.[2] The 
risk increases with age to the seventh decade of life, but afterwards we can observe a decrease 
in its prevalence. In comparison to other European Union countries in Poland the average 
incidence of breast cancer is 35% lower, while mortality is 20% lower than in other countries. 
[3] The peak of breast cancer incidence is 55-69 years. Currently, we can observe an increase 
in the occurrence of breast cancer, while from the mid-90s of the last century, the mortality 
decreased [2,3]. 
Despite the fact that the causes of the disease remain unknown, risk factors contributing to its 
development have been identified. The risk of becoming ill increases with age, which is 
considered as the most significant factor among all. The incidence of breast cancer in women 
before the age of 35 is estimated to be about 1-3% and most often concerns cases of aggressive 
biology as well as cases on the hereditary basis. The majority of cases concern women after 
their 50s. Women in the age of 50-59 are 32% of all patients. [4,5,6] The incidence of breast 
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cancer in the family is also an important risk factor, especially in first degree relatives. Such 
relationship can be observed even in 25% of patients.[4] The likelihood of developing this 
cancer increases with the number of first-degree relatives who have been affected.[1] Other 
particularly important risk factors include the presence of breast cancer in anamnesis, atypical 
hyperplasia, high-density breasts, and exposure to ionizing radiation.[4] Type of lifestyle also 
has a significant impact on the development of the disease. Research indicates relationship 
between increased percentage of illness and the intake of large amounts of fats in the diet, 
obesity, smoking and alcohol consumption [1]. 
The risk of developing breast cancer is also increased by the early age of menarche and the 
menopause in late life, which is related to the prolongation of exposure time of the sensitive 
mammary gland to the hormones produced by the ovary - estrogen and progesterone.[1] Also 
the age at which the woman gave birth to the first child is significant. Women who have been 
pregnant for the first time after their 30s have two times higher risk of cancer development than 
women who gave birth for the first time in their 20s. Long-term exposure to estrogens is a 
documented risk factor which has led researchers to study the effects of hormone replacement 
therapy (HRT) and hormonal contraception on the incidence of breast cancer. There was 
observed an increased risk of developing this tumor in women using HRT, while exposure 
lasting less than 5 years was not associated with a significant increase in cancer development. 
[4,7] Moreover according to American scientists the risk of using HTR less than five years is 
smaller than the risk related to obesity and alcohol consumption. What is crucial among patients 
using HTR there have been observed more often mammography examination, which influences 
on cancer’s detection rate.  [4,8] The majority of studies concerning oral hormonal 
contraception (HTA) did not show a significant increase in the incidence of women taking it, 
but there was identified a group of patients in whom this therapy may increase the risk up to 
70%. It includes patients who do not become pregnant [7,9]. The period of use of HTA up to 2 
years has been considered safe, while patients taking HRT beyond 8 years are said to be exposed 
to an increased risk of disease by up to 46% [4]. 
Genetic background of breast cancer is found in approximately 5-10% of cases. The most 
significant risk factor for the development of hereditary cancer is an emergence of mutations in 
suppressor genes BRCA1 and BRCA2. These genes show biological activity including repair 
of damaged DNA. On the other hand, an occurrence of mutations is responsible for 
development  of genetically conditioned co-existing breast and ovarian cancer [10]. That may 
lead to emergence of either breast cancer, ovarian cancer or these two tumors simultaneously 
among women within one family. Additionally, a characteristic trait is young age of tumor 
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development and its aggressive course. Ovarian cancer associated with BRCA1 and BRCA2 
mutations has specific phenotype - the most common is serous and endometroid cancer 
[11,12,13]. Moreover, these genes are probably related to primary Fallopian tube cancer and 
peritoneal cancer [14]. The occurrence of this mutation increases the risk of both- breast cancer 
to 80% and ovarian cancer to 30%. References indicate that among the carriers of BRCA1 gene, 
the incidence of breast cancer is estimated around 65% among 70-year-old women. Regarding 
women with BRCA2 mutation, the value is lower and concern approximately 45% of cases 
[10]. An individual risk index of patients with mutations is difficult to estimate as around 2000 
variants of mutations have been found in these genes. The studies indicated that the place where 
mutant variant is located, may have a greater risk of developing breast cancer [10,15,16]. 
Moreover, recent researches suggest that the risk factors of breast cancer may influence carriers 
of BRCA1 and BRCA2 in different way than women that do not have mutation [17]. 
Additionally, other genes may  induce the development of the illness- ATP, BRIP1, TP3, CHEK 
i PTEN [1]. 
 
Tamoxifen 
Due to the fact that time in which female sex hormones affect mammary gland is one of the 
most important risk factor of breast cancer development, more researchers focused on the use 
of drugs such as selective estrogen receptor modulators (SERMs) in prevention breast cancer. 
Distinctive interest concerns the application of tamoxifen that has been used as an element of 
combined oncological treatment. The use of tamoxifen in breast cancer prophylaxis could be a 
breakthrough in oncology and reduce the number of new cases in significant rate [18]. 
Tamoxifen has antiestrogenic effect. It combines competitively with estrogen's receptors in 
tissues of the cancer that express them. That results in the inhibition of both- growth factors 
release and synthesis by the tumour [18]. Moreover This drug works as agonist, replacing 
oestrogen to many tissues, such as the ones in liver, bone, breast and uterus. [2]Additionally, 
tamoxifen stimulates the development of progesterone receptors. Its action leads to inhibition 
of tumour cells division in breast. Moreover, it increases the concentration of  sex hormone 
binding globulin that results in the decrease of free estradiol level in a plasma. That causes the 
stimulation of anterior pituitary gland that results in FSH secretion which stimulates the ovaries 
to secrete estrogens in premenopausal period. What is more, tamoxifen has an impact on the 
release of transforming growth factor β (TGF-β) that contributes to its antineoplastic activity 
[18]. 
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Tamoxifen is well absorbed from the digestive tract and reaches maximum concentration 
around 4-7 hours after oral administration. The half-life is 7-14 days. It binds to 99% of plasma 
proteins. The main metabolite of tamoxifen is demethylamamoxifen that has similar activity. 
The drug is excreted mainly in form of metabolites along with faeces [18]. 
Tamoxifen is a first-line drug for a women with positive oestrogen receptor breast cancer. 
According to researches, it does not work for oestrogen receptor negative breast cancer. [19]. 
This drug works as agonist, replacing oestrogen to many tissues, such as the ones in liver, bone, 
breast and uterus [20]. It is estimated, that this therapy decreases the currency of a breast cancer 
for about 50% [21,22]. Among women in pre menopause period, tamoxifen can be an 
alternative to oophorectomy or ovarian irradiation. As reported by many researchers, we can 
also use it as an induction of an ovulation, and in therapy of mastalgia and mastopaty. This kind 
of therapy has also utilisation in decreasing the risk of a breast cancer among women with 
carcinoma in situ after the operation and radiotherapy, or belonging to high-risk group [18]. 
 
Side effects 
Side effects of tamoxifen therapy are rare, but it is recommended to just lower the dose of the 
drug to reduce the symptoms. Women treated with tamoxifen, had higher risk of endometrial 
cancer, especially those over the age of 50. Moreover, they were more prone to have deep 
venous thrombosis and pulmonary embolism. [23] One of the Italian randomised study, 
indicates that patients taking tamoxifen, were more likely to have hot flashes and urinary 
disturbances. The same research suggested that women with this therapy had more 
thromboembolic events, cardiac arrhythmia, atrial fibrillation and higher risk of 
hypertriglyceridemia [24] However, some of the results revealed, that tamoxifen therapy when 
stopped, discontinued to cause deep vein thrombosis and pulmonary embolism. [25,26] It is 
also common to have vasomotor symptoms, because of the lack of oestrogenes, such as redness 
of a face, rash, nausea, vomiting, dizziness and headaches, menstrual disorders or bone pain 
[18]. 
 
The use of tamoxifen as a breast cancer prophylaxis 
In the literature there are more and more frequent reports about the effectiveness of tamoxifen 
in the prevention of breast cancer. Tamoxifen is considered to be a pioneering drug as it is use 
in combined breast cancer therapy and also in chemoprophylaxis. Anti‑estrogen therapy can be 
usage in the types of cancers associated with hormones as well as for tumors showing estrogen 
receptor expression [27]. Due to the fact that the drug has both estrogenic and antiestrogenic 
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activity, it seems that it’s use can bring significant benefits, but it also has side effects. Most of 
the studies focuses on understanding the benefit / risk ratio and tries to define groups, which 
probably could take advantage of. In many randomized trials, the effectiveness of the drug in 
reducing the risk of cancer development has been proven [28]  Food and Drug Administration 
(FDA) considered the medicine as a chemoprophylaxis in 1998. They classified women in the 
pre- and postmenopausal period with ,increased hereditary risk of breast cancer [29,30]. The 
decision was based on the result of study which was carried out by the United States National 
Cancer Institute. The research was ended earlier because as an intervening study showed that 
tamoxifen lowered breast cancer prevalence by almost one half [22,29]. 
A few prospective randomized trials have been conducted to test the effectiveness of the drug 
in prevention of breast cancer [31]. One of one of the aforementioned tests was conducted by 
The National Surgical Adjuvant Breast and Bowel Project P-1 study (NSABP-P1) in 1992. 
They qualified randomized 13,388 women with a 5-year predicted breast cancer risk of at least 
1.66% by the modified Gail model. After a follow-up of 54.6 months on average, a 49% 
decrease in risk was seen in the tamoxifen group. It was proved that tamoxifen had reduced risk 
in all age groups in patients with a history of lobular carcinoma in situ (LCIS) or atypical ductal 
hyperplasia. It was also considered to be effective with women, who had high classification of 
predicted 5-year risk. However there was no significant change in risk in ER-negative tumors  
[29].  
The Italian Randomized Tamoxifen Prevention Trial, which enrolled 5408 participants, initially 
did not show the efficacy of tamoxifen in reducing risk. The study involved also women with 
low-to-normal risk of breast cancer. Notwithstanding, after 11 years of observation scientist 
verified a statistically significant reduction in the prevalence of ER-positive breast cancer 
among patients with high risk who received the drug [32,33]. 
The Royal Marsden Hospital Tamoxifen Chemoprevention Trial failed to demonstrate 
effectiveness of the medicine in the beginning. It randomized 2494 women  who were 30-70 
years old and had a family history of breast cancer. In 2007 the up-date of this trial was 
published and it showed that tamoxifen had reduced a risk of the ER-positive cancer based on 
the conclusions from 20 years of observation [34,35]. 
In the years 1992-2001 The International Breast cancer Intervention Study I (IBIS-I) was 
conducting a research, to which women were qualified who had a family history of breast 
cancer. Participants were devoted into 2 groups. One of these groups received the drug at 20 
mg daily for 5 years , while the second group received a placebo for the same time. 7154 
women, who were examined have been observed on average for 16 years. The results of this 
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research were promising. It was found that group who had received tamoxifen had significantly 
lower risk of developing breast cancer compared to those receiving placebo. Risk decrease was 
remarkably visible in the case of invasive oestrogen receptor-positive breast cancer. There was 
also a lower risk of developing ductal carcinoma in situ (DCIS), but only in the first 10 years 
of observation. What it is more, the study showed lower risk of gastrointestinal cancer. However 
there was no significant difference in the incidence of invasive oestrogen receptor-negative 
breast cancer. What is important, no statistically significant difference in the incidence of 
cerebral, vascular or death was found, however, the incidence of deep vein thrombosis was 
more frequent in the tamoxifen group. The published study proves that tamoxifen is effective 
in reducing the risk of breast cancer [36,37]. 
Tamoxifen gives long-term defence and is the only proven preventive therapy for 
premenopausal women. What is more, the lasting long-standing effect is not only seen during 
treatment, but it also persists in the 5 years after therapy was completed. Furthermore after the 
end of tamoxifen therapy almost all side-effects cease [38]. In recent years, the National 
Institute for Health and Care Excellence in the United Kingdom has published guidelines, which 
recommend using the drug for 5 years for women with a 30% lifetime risk of breast cancer and 
probably with women who have a 19% lifetime risk and do not have increased risk of 
thromboembolic diseases [39]. It is established that tamoxifen reduce the risk of contra-lateral 
breast cancer and it is even more effective than contra lateral prophylactic mastectomy [40]. 
 It is also recognized that tamoxifen prevents the development of breast cancer to the same 
extent as prophylactic adneksectomy in women with the highest genetic risk of breast cancer 
[41,42,43]. Data on the effectiveness of the drug in primary prevention in patients with inherited 
mutations come mainly from trials conducted by Royal Marsden [44] and NSABP-P1 [45]. 
Trials which enrolled 2464 mutation carriers presented that the medicine lowered the risk of 
development of contra-lateral breast cancer in women who had suffered from the disease 
[46,47]. Majority of breast cancer with BRCA1 mutation is ER-negative, while tamoxifen is 
considered to be the most effective with cancer what express estrogen receptors. This prompted 
researchers to study the effectiveness of the drug in BRCA1 carcinomas. Collected data 
suggested that the medicine can decrease hormone receptor negative tumors in BRCA1 
mutation carriers as well [47]. It also indicated that estrogen plays a huge role in the beginning 
of oncogenesis processes of tumors with BRCA1 mutations [48]. Tamoxifen has no impact on 
decreasing the risk of development ovarian cancer in women with BRCA1 and BRCA2 
mutations, however increases the risk of endometrium cancer several times [29,41,49]. The 
three years of application of the drug protects patients with these mutations against breast cancer 
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for a period of 10 years. Such prevention is recommended for patients from 35 to 40 years old, 
but it is not widely used. In the United States group, which could have some benefits from this 
therapy is significantly limited [30]. Tamoxifen should be considered with patients with 
BRCA1 and BRCA2 mutations who refuse bilateral mastectomy or want to significantly delay 
it. Especially in the case of for premenopausal women this therapy can bring meaningful 
benefits and risk of important side effects is potentially small. For mutation carriers who have 
been identified with hormone receptor positive tumors, the medicine is believed to be a standard 
of care [48,50]. 
The main limitation in the use of tamoxifen by patients from high-risk groups and their doctors 
is the fear of side effects. One of proposed strategies to improve benefit-risk ratio was to use 
the drug at low doses to minimize the risk of undesirable consequences of therapy. Carried out 
researches reports that low-dose tamoxifen therapy can reduce toxicity of the drug, while the 
biological activity is retained. [48]. The conventional dose used for prophylaxis is 20 mg/day. 
It was found that efficacy of 20 mg/day of tamoxifen is comparable to that of upper doses of 
the drug (30-40 mg/day) [51]. Interestingly, data from animal studies suggested that reducing 
the dose of the drug up to 1 mg does not involve a significant reduction in the effectiveness of 
the drug [52]. On the other hand, the minimum active dose of the drug has not been determined 
so far. In order to investigate whether the reduction of the standard dose in prophylaxis reduces 
the activity of the drug, several studies have been carried out. They assessed the effect of 
different doses of the drug on different biomarkers such as IGF-1 and Ki-67, which were known 
to be favourably touched by conventional tamoxifen dose [48]. In 1992 Decensi et al. were 
investigating associations between various doses of the drug and biomarkers. They didn’t 
manage to observe a significant change in levels of biomarkers, which was caused by different 
tamoxifen dose. The only response was seen for the ratio of IGF-1/IGF binding proteins 
(IGFBP)-3 [53]. In 2003 they found that effect on Ki-67 expression of the lower dose of the 
medicine is comparable to the higher dose [54]. The other studies also showed that minor dose 
of the drug had no impact on the activity in prophylaxis [55]. 
 
Conclusions 
Breast cancer, which is currently the most common tumour in the globe, is a serious worldwide 
public health quandary. The use of tamoxifen seems to be a breakthrough in its treatment and 
prevention. The drug, in addition to using it as adjuvant therapy for breast cancer, can be used 
as a prophylactic of the disease. Tamoxifen can stop the development of the disease and reduce 
the risk of its occurrence in women at high risk. In a few randomized trials on large groups 
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researches demonstrated effectiveness of the medicine and benefits of therapy. The results 
substantially improve benefit-risk ratio, but every case of using tamoxifen should be considered 
individually to assess it. Serious side effects such as thromboembolic complications, 
endometrium cancer or thrombocytopenia are rarely reported. Redness of the face, flushing, 
rash, nausea, vomiting, dizziness and headaches are the most common aftereffects. Younger 
women are less affected by the adverse effects of therapy. Tamoxifen can bring visible 
advantages especially to premenopausal women, who are more tolerant of treatment. The drug 
is particularly beneficial for patients with a family history of breast cancer and carriers of the 
BRCA1 and BRCA2 mutation. The main limitation of its use is the fear of side effects. Both 
patients and physicians should be educated about the benefits of this therapy. Tamoxifen 
prophylaxis is generally available and low cost. Its global introduction can significantly reduce 
the number of new cases and protect the patient against aggravating treatment. 
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